Why Farbe Firma is the Top Manufacturer of Sugammadex Sodium Injection
- Maulik Sudani
- 24 hours ago
- 7 min read
Last Updated: June 15, 2026
TL;DR: Sugammadex Sodium Injection — a sterile, clear, colourless to slightly yellow-brown aqueous solution of sugammadex sodium, a selective relaxant binding agent (a modified gamma-cyclodextrin), supplied commonly as a 200 mg/2 mL vial and a 500 mg/5 mL vial (100 mg/mL) for single intravenous bolus injection — is the anaesthesia agent clinicians use to rapidly reverse rocuronium- or vecuronium-induced neuromuscular blockade, restoring normal muscle function at the end of surgery or when blockade must be reversed urgently. Because the dose is given as a single intravenous bolus and recovery of breathing and muscle strength depends on a precise, reproducible amount, each vial must deliver an exact, sterile, particulate-free dose at the labelled concentration, with the assay, the impurity and degradation profile, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Sugammadex Sodium Injection at our Gujarat, India facility and supplies it to hospital pharmacy, anaesthesia, operating-theatre and critical-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Selective relaxant binding agent (modified gamma-cyclodextrin) — Sugammadex Sodium Injection is given as a single intravenous bolus to rapidly reverse rocuronium- or vecuronium-induced neuromuscular blockade, restoring spontaneous breathing and muscle strength at the end of anaesthesia or when reversal is needed urgently.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated solution compounding and vial filling lines, control of the stability-indicating assay, the impurity profile, solution pH, fill volume, particulate and endotoxin for a small-volume parenteral, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready vial packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Sugammadex Sodium Injection Demands a Premium Manufacturer
Sugammadex Sodium Injection holds a dependable, increasingly central place in anaesthesia, operating-theatre and critical-care practice across every market. It is the intravenous selective relaxant binding agent that anaesthetists reach for when rocuronium- or vecuronium-induced neuromuscular blockade must be reversed quickly and predictably — at the routine end of surgery, when deep blockade must be unwound, or in a 'cannot intubate, cannot ventilate' emergency where rapid reversal can be life-saving. Given as a single intravenous bolus, sugammadex encapsulates the circulating aminosteroid muscle relaxant and removes it from the neuromuscular junction, so spontaneous breathing and muscle strength return within minutes. In each of these settings the dose delivered from each vial must be exact, sterile, particulate-free and reliably the same from unit to unit, because reliable recovery of respiration depends on a precise, reproducible dose at a defined milligram-per-kilogram level.
That clinical reality places real demands on the manufacturer. The product is presented as a low-volume aqueous solution that must stay clear, within a defined colour range and within a defined pH window throughout shelf life, and must remain compatible with the common diluents into which it may be mixed. The assay of sugammadex must be exact; the impurity and degradation profile must stay within tight limits; the pH and the deliverable volume must be controlled tightly so each vial gives the labelled dose at the labelled concentration; the solution must be free of visible and sub-visible particulates and low in endotoxin; and it must be sealed in a vial whose container-closure integrity holds across shelf life. Choosing a Sugammadex Sodium Injection manufacturer that treats the stability-indicating assay, pH and fill-volume control, the validated sterilisation route, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Sugammadex Sodium Injection Manufacturer Apart
A world-class manufacturer of Sugammadex Sodium Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of sugammadex with the tight related-substance and degradation-product control by HPLC that a parenteral reversal agent demands, a robust, validated aseptic solution-fill process — with terminal moist-heat sterilisation where the formulation and container permit it, otherwise sterile filtration and aseptic filling — that protects the assay, the pH and the clarity of the solution, and tender-ready dossier support for a hospital-formulary anaesthesia product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial- or in-house-specification-grade sugammadex sodium sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the dose. The bulk solution is compounded in water-for-injection at the controlled pH that keeps sugammadex sodium stable and fully in solution, sterile-filtered through 0.22 µm membrane, and filled into vials under ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified, otherwise full aseptic processing — locked in the master batch record. Filled vials are 100 % inspected for fill, seal, clarity, colour and particulate defects; in-process and release testing confirm the assay of sugammadex by validated HPLC, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and endotoxin is held well within limits so the solution is safe for intravenous bolus administration. Because the product is given as a weight-based bolus, deliverable-volume accuracy and dose reproducibility are confirmed and documented for the prescriber.
Quality Systems Behind Every Sugammadex Sodium Injection
Every Farbe Firma Sugammadex Sodium Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of sugammadex against reference standards, control of related substances and degradation products by HPLC, solution pH, deliverable (fill) volume, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated vial-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because sugammadex is given to restore breathing and muscle strength and the assay, pH, clarity and particulate burden of the solution drive both efficacy and safety, we treat the stability-indicating HPLC assay, the solution pH, the deliverable volume and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and in-use dilution stability is established where dilution is supported.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Sugammadex Sodium Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad small-volume parenteral portfolio across anaesthesia, critical-care, anti-infective and supportive-care categories. For Sugammadex Sodium Injection specifically, we supply the 200 mg/2 mL and 500 mg/5 mL (100 mg/mL) single-dose vials of sterile solution under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Sugammadex Sodium Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control, pH and solubility design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose control, dilution-compatibility and in-use stability, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a parenteral reversal agent where assay accuracy, pH and particulate control directly govern both the speed of recovery and patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Sugammadex Sodium Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Sugammadex Sodium Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, dedicated solution compounding and vial filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Sugammadex Sodium Injection do you supply?
Our standard presentations are the 200 mg/2 mL and 500 mg/5 mL (100 mg/mL) single-dose vials of sterile sugammadex sodium solution, for single intravenous bolus injection. Custom strengths, fill configurations, vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Sugammadex Sodium Injection mainly used for?
Sugammadex Sodium Injection is used to rapidly reverse rocuronium- or vecuronium-induced neuromuscular blockade, given as a single weight-based intravenous bolus at the end of surgery or when reversal is needed urgently. Farbe Firma verifies the assay, clarity, colour, deliverable volume, pH and particulate matter at release so each vial delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Sugammadex Sodium Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Sugammadex Sodium Injection contract manufacturing?
MOQs vary by strength, vial size, sterilisation route, label complexity and dossier requirements. For our small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments